LONDON, UK I November 21, 2024 I Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ...
BOSTON, MA, USA I November 20, 2024 I LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration ...
NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
TOKYO, Japan and CAMBRIDGE, MA, USA I November 14, 2024 I Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, ...
AURORA, CO, USA I November 21, 2024 I OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced today the closing of a Series A extension financing led by existing ...
Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – ...
Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...
Collaboration will combine Vyriad's lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback